Session

IBD (Posters)

IN CONTRAST TO FAECAL CALPROTECTIN (FC), INCREASED FAECAL APHA-1-ANTITRYPSIN (A1AT) EXCRETION IS ASSOCIATED WITH LOW THROUGH LEVELS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS LACKING RESPONSE TO MONOCLONAL ANTIBODY (MAB) THERAPY
IN CONTRAST TO FAECAL CALPROTECTIN (FC), INCREASED FAECAL APHA-1-ANTITRYPSIN (A1AT) EXCRETION IS ASSOCIATED WITH LOW THROUGH LEVELS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS LACKING RESPONSE TO MONOCLONAL ANTIBODY (MAB) THERAPY

NO ASSOCIATION BETWEEN POST-INFLAMMATORY PSEUDOPOLYPS AND COLORECTAL NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
NO ASSOCIATION BETWEEN POST-INFLAMMATORY PSEUDOPOLYPS AND COLORECTAL NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

KNOCKDOWN OF MUC1 AND MUC13 IN INFLAMED INTESTINAL EPITHELIAL CELLS AFFECTS EXPRESSION OF KEY GENES INVOLVED IN INTESTINAL BARRIER HOMEOSTASIS
KNOCKDOWN OF MUC1 AND MUC13 IN INFLAMED INTESTINAL EPITHELIAL CELLS AFFECTS EXPRESSION OF KEY GENES INVOLVED IN INTESTINAL BARRIER HOMEOSTASIS

WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

TIME TRENDS FOR POSTOPERATIVE RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN'S DISEASE: DETAILED EVALUATION OF ASSOCIATED FACTORS
TIME TRENDS FOR POSTOPERATIVE RECURRENCE AFTER ILEOCECAL RESECTION IN CROHN'S DISEASE: DETAILED EVALUATION OF ASSOCIATED FACTORS

TRANSCRIPTOMIC INSIGHT INTO IN VITRO INTERACTION OF ESCHERICHIA COLI WITH IMMUNOGLOBULIN A AS A MODEL OF THE INFLAMMATORY BOWEL DISEASE PATHOGENESIS
TRANSCRIPTOMIC INSIGHT INTO IN VITRO INTERACTION OF ESCHERICHIA COLI WITH IMMUNOGLOBULIN A AS A MODEL OF THE INFLAMMATORY BOWEL DISEASE PATHOGENESIS

OVERABUNDANCE OF SERUM IMMUNOGLOBULIN G SPECIFIC TO ESCHERICHIA COLI STRAINS AS ONE OF THE FEATURES OF CROHN_S DISEASE
OVERABUNDANCE OF SERUM IMMUNOGLOBULIN G SPECIFIC TO ESCHERICHIA COLI STRAINS AS ONE OF THE FEATURES OF CROHN_S DISEASE

ENDOSCOPIC AND HISTOLOGIC ACTIVITY ASSESSMENT CONSIDERING DISEASE EXTENT AND PREDICTION OF TREATMENT FAILURE IN ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC ACTIVITY ASSESSMENT CONSIDERING DISEASE EXTENT AND PREDICTION OF TREATMENT FAILURE IN ULCERATIVE COLITIS

SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501
SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

EVALUATION OF THE ROLE OF ENTERIC NEURONS AND INTERSTITIAL CELLS IN COLONIC INFLAMMATION IN THE MOUSE MODEL OF DSS-INDUCED COLITIS
EVALUATION OF THE ROLE OF ENTERIC NEURONS AND INTERSTITIAL CELLS IN COLONIC INFLAMMATION IN THE MOUSE MODEL OF DSS-INDUCED COLITIS

EFFECTIVENESS OF USTEKINUMAB ON CROHN_S DISEASE ASSOCIATED SPONDYLOARTROPATHY
EFFECTIVENESS OF USTEKINUMAB ON CROHN_S DISEASE ASSOCIATED SPONDYLOARTROPATHY

CLINICAL RESPONSE TO AZATHIOPRINE IS ASSOCIATED WITH SPECIFIC METABOLIC SHIFT TOWARDS THIOGUANINE DI- AND TRI-PHOSPHATES
CLINICAL RESPONSE TO AZATHIOPRINE IS ASSOCIATED WITH SPECIFIC METABOLIC SHIFT TOWARDS THIOGUANINE DI- AND TRI-PHOSPHATES

SYSTEMIC AND ORALLY ADMINISTRATION OF AC2-26 LOADED NANOPARTICLES INDUCES ANASTOMOTIC HEALING IN A MODEL OF LOCALLY INDUCED TNBS COLITIS
SYSTEMIC AND ORALLY ADMINISTRATION OF AC2-26 LOADED NANOPARTICLES INDUCES ANASTOMOTIC HEALING IN A MODEL OF LOCALLY INDUCED TNBS COLITIS

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAÏVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAÏVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

EXPLORING HYPOPHOSPHATAEMIA: HOW FREQUENTLY DOES IT OCCUR IN INFLAMMATORY BOWEL DISEASE AND WHAT ARE THE IMPLICATIONS FOR INTRAVENOUS IRON THERAPY?
EXPLORING HYPOPHOSPHATAEMIA: HOW FREQUENTLY DOES IT OCCUR IN INFLAMMATORY BOWEL DISEASE AND WHAT ARE THE IMPLICATIONS FOR INTRAVENOUS IRON THERAPY?

SEROLOGICAL MARKERS OF EXTRACELLULAR MATRIX REMODELING REFLECTS ENDOSCOPIC DISEASE ACTIVITY AND SEVERITY IN CROHN'S DISEASE AND ULCERATIVE COLITIS
SEROLOGICAL MARKERS OF EXTRACELLULAR MATRIX REMODELING REFLECTS ENDOSCOPIC DISEASE ACTIVITY AND SEVERITY IN CROHN'S DISEASE AND ULCERATIVE COLITIS

PERIANAL CROHN'S DISEASE IN CHILDREN IS ASSOCIATED WITH MORE HOSPITALIZATIONS AND SURGERIES DESPITE HIGHER UTILIZATION OF IMMUNOMODULATORS AND BIOLOGICS: A REPORT FROM THE EPIIIRN COHORT
PERIANAL CROHN'S DISEASE IN CHILDREN IS ASSOCIATED WITH MORE HOSPITALIZATIONS AND SURGERIES DESPITE HIGHER UTILIZATION OF IMMUNOMODULATORS AND BIOLOGICS: A REPORT FROM THE EPIIIRN COHORT

HISTOLOGICAL ACTIVITY SCORE IN CROHN'S DISEASE: A REAL LIFE 1-YEAR PROSPECTIVE STUDY
HISTOLOGICAL ACTIVITY SCORE IN CROHN'S DISEASE: A REAL LIFE 1-YEAR PROSPECTIVE STUDY

THE INCIDENCE AND CHARACTERISTICS OF VENOUS THROMBOEMBOLISMS IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE
THE INCIDENCE AND CHARACTERISTICS OF VENOUS THROMBOEMBOLISMS IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE

Item 141 - 160 / 558
1 2 3 4 5 6 7
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28